Myriad Genetics Earns 2024 Great Place To Work® Certification™
July 02 2024 - 9:00AM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced it has received the Great
Place To Work Certification for the second year in a row. The
certification is based entirely on what current employees say about
their experience working at Myriad. This year, 84% of employees
said it’s a Great Place To Work – 27 percentage points higher than
the average U.S. company.
“It’s rare to work somewhere where everyone is so
positive and loves their job, but Myriad truly is special,” shared
a current Myriad Genetics employee in the anonymous survey. “Every
single person I have met so far has been more than pleasant,
welcoming and accommodating to me. My opinions and preferences are
taken into consideration. I'm not scared to ask questions and I am
happy to sign into work each day. Also, this company seems to truly
care about work/life balance and inclusion, rather than treating it
as a check list item.”
Great Place To Work is the global authority on
workplace culture, employee experience, and the leadership
behaviors proven to deliver market-leading revenue, employee
retention and increased innovation.
“At Myriad Genetics we are committed to fostering an open,
collaborative and inclusive work environment where all teammates
have an equal opportunity to grow and make a difference in our
patients’ lives,” said Shereen Solaiman, chief people officer,
Myriad Genetics. “The Great Place to Work Certification is a
testament to the passion, talent and hard work our teammates bring
to the Myriad workforce every day to fulfill our mission to advance
health and well-being for all.”
"Great Place To Work Certification is a highly coveted
achievement that requires consistent and intentional dedication to
the overall employee experience," says Sarah Lewis-Kulin, the Vice
President of Global Recognition at Great Place To Work. “By
successfully earning this recognition, it is evident that Myriad
Genetics stands out as one of the top companies to work for,
providing a great workplace environment for its employees."
For more information about careers at Myriad, please
visit: https://myriad.com/careers/
About Myriad
Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
About Great Place to Work Certification™Great
Place To Work® Certification™ is the most definitive
“employer-of-choice” recognition that companies aspire to achieve.
It is the only recognition based entirely on what employees report
about their workplace experience – specifically, how consistently
they experience a high-trust workplace. Great Place to Work
Certification is recognized worldwide by employees and employers
alike and is the global benchmark for identifying and recognizing
outstanding employee experience. Every year, more than 10,000
companies across 60 countries apply to get Great Place To
Work-Certified.
About Great Place To Work®As the global
authority on workplace culture, Great Place To Work® brings 30
years of groundbreaking research and data to help every place
become a great place to work for all. Their proprietary platform
and For All™ Model helps companies evaluate the experience of every
employee, with exemplary workplaces becoming Great Place To Work
Certified™ or receiving recognition on a coveted Best Workplaces™
List.
Learn more at greatplacetowork.com and follow Great Place To
Work on LinkedIn, Twitter, Facebook and Instagram.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to Myriad’s commitment to fostering an open,
collaborative and inclusive work environment where all teammates
have an equal opportunity to grow and make a difference in
patients’ lives. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on February 28, 2024, as well as
any updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
Investor Contact |
Media
Contact |
Matt Scalo |
Glenn Farrell |
(801) 584-3532 |
(385) 318-3718 |
IR@myriad.com |
PR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Jul 2023 to Jul 2024